NBIX Price Prediction Next Week
Technical Analysis: NBIX has experienced a significant decline, falling 19.23% last week after missing Q4 revenue estimates. The stock is currently trading at $122.14, well below its 200-day moving average of $133.82, indicating a bearish trend. The RSI-14 reading of 26.26 suggests the stock is oversold.
News Impact:
- Q4 2024 earnings report showed mixed results with EPS beating estimates ($1.69 vs $1.56) but revenue missing slightly ($627.7M vs $628.99M)
- 2025 Ingrezza sales guidance of $2.5B-$2.6B came in below Street estimates of $2.67B
- Multiple analysts have lowered price targets:
- BofA: $184 to $179
- HC Wainwright: $190 to $185
Price Prediction for Next Week: Based on Fibonacci levels and current market conditions:
- Support levels: $127.53 (S1), $119.30 (S2)
- Resistance levels: $154.15 (R1), $162.38 (R2)
Trading Recommendation: SELL Rationale:
- Breaking below 200-day MA indicates strong bearish momentum
- Conservative revenue guidance suggests near-term growth challenges
- Multiple analyst downgrades reflect reduced confidence
- Technical indicators show continued downward pressure
Price Target: $119.30 (S2 level) in the next trading week, with potential for further decline if broader market weakness persists.
NBIX Similar Chart Price Prediction
The price of NBIX is predicted to go up -28.68%, based on the high correlation periods with TLPH. The similarity of these two price pattern on the periods is 96.68%.
NBIX
TLPH
Down: -28.68%Similarity: 96.68%
NBIX Revenue Forecast
NBIX EPS Forecast
NBIX FAQs
What is bull’s view on NBIX?
What is bear's view on NBIX?
What is NBIX revenue forecast for next quarter？
What is NBIX eps forecast for next quarter？
NBIX Analyst's Forecast
Ashwani Verma
UBS
Strong Buy
2025-01-08
Price Target
$142 → $162
Upside
+16.79%
UBS analyst Ashwani Verma raised the firm's price target on Neurocrine to $162 from $142 and keeps a Buy rating on the shares as part of a broader note on the U.S. Pharmaceuticals and Biotechnology industry. The firm believes BioPharma will find it difficult to outperform against a more uncertain macro backdrop in the short-term, and thinks President-elect Trump will be capable of enacting significant legislative change, and that unpredictability is expected to cast a shadow over the space, the analyst tells investors in a research note. There will be continued uncertainty in the space until there is more clarity on Trump's changes, UBS says.
Carter Gould
Barclays
Buy
2024-12-23
Price Target
$160 → $165
Upside
+20.45%
Evan Seigerman
BMO Capital
Hold
2024-10-17
Price Target
$128 → $114
Downside
-3.76%
